Participation of clinical pharmacists in QTc interval prolongation induced by gilteritinib
10.12206/j.issn.2097-2024.202309050
- VernacularTitle:临床药师参与吉瑞替尼致QTc间期延长的病例分析
- Author:
Xiaolin CUI
1
;
Xiaofei FU
2
;
Yanhong DU
2
;
Juan LIU
2
;
Qian ZHU
1
;
Ziqi LIU
2
Author Information
1. No. 63680 Hospital of the PLA, Wuxi 214400, China.
2. Characteristic Medical center of Rocket Force, Beijing 100088, China.
- Keywords:
gilteritinib;
QTc interval prolongation;
adverse drug reaction;
clinical pharmacists
- From:
Journal of Pharmaceutical Practice and Service
2024;42(6):263-266
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the role of clinical pharmacists involved in the case of a patient with acute myeloid leukemia whose QTc interval prolongation was induced by gilteritinib, and to provide reference for drug treatment and monitoring of those patients. Methods The abnormal electrocardiogram （ECG） of a patient with acute myeloid leukemia was found in time by clinical pharmacists, who participated in clinical diagnosis and treatment by analyzing the patient’s underlying diseases, diagnosis and treatment process, therapeutic drugs and their potential interactions. Results Clinical pharmacists suspected that the prolonged QTc interval was likely to be an adverse reaction caused by gilteritinib, and recommended immediate discontinuation of the drug and re-examination of the electrocardiogram.The physician took the suggestion to stop the suspected drug therapy with gilteritinib promptly, and ECG was rechecked 3 d later, and the QTc value returned to the normal range. Conclusion Clinical pharmacists participating in clinical diagnosis and treatment could provide better pharmaceutical care for patients.
